Latest Cost Management News

Enlitic, Inc. reported a strong quarter with record cash receipts and contract wins, yet withdrew its revenue guidance due to delayed project completions. The company remains confident in reaching operational cash flow break-even by the end of Q4 FY25.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug candidate NUZ-001 and strengthened its balance sheet with a $5.2 million capital raise. The company is now poised to enter the pivotal HEALEY ALS Platform Trial, marking a significant step forward in its neurodegenerative disease program.

Australian Bond Exchange Holdings (ASX – ABE) unveiled new AUD-denominated market-linked securities and progressed its AI-driven credit analysis tool, while reporting a $0.7 million quarterly cash outflow and plans for capital raising.

BSA Limited’s Q1 FY2026 results reveal a sharp revenue drop following the expiration of its key nbn contract, alongside a major workforce reduction and strategic pivot.

Aspermont Limited reports its 37th consecutive quarter of subscription growth, launching its Mining-IQ AI platform and securing a landmark $550k contract with Rio Tinto.

Hydralyte USA reported a 6% year-on-year sales increase in Q3 FY25 alongside a significant 42% reduction in operating cash burn, driven by a streamlined US-focused model and new product launches in brain and gut health.

Cluey Ltd has reported its strongest-ever underlying EBITDA alongside improved cash flow, while ramping up investments in AI-powered product development set to launch in 2026.

Aumake Limited reported a near-breakeven quarter with strong cash receipts and launched a new health product brand while securing a strategic partnership to expand Australian agricultural exports to China.

Nanoveu Limited has reported a major leap in drone endurance through its ultra-low-power AI chip technology, alongside advancing its next-generation 16 nm chip towards fabrication and expanding its U.S. sales network.

Vectus Biosystems has signed a binding agreement to sell its VB4-P5 renal fibrosis compound to Canadian biotech XORTX Therapeutics, while actively pursuing licensing opportunities for its lead drug VB0004 and others, particularly in China.

Entertainment Rewards Ltd reported a 2.2% revenue increase in Q1 FY26, driven by strong membership growth and Card Linked Offers, while securing an additional $3 million loan to support its strategic initiatives.

AUCyber Limited reports a rise in customer receipts and improved operating cash flow in Q1 FY26, following strategic exits from low-margin contracts and a focus on cybersecurity services.